Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2017—Quidel announced a revised definitive agreement with Alere for its pending acquisition of Alere’s B-type Natriuretic Peptide assay business run on Beckman Coulter analyzers under which post-acquisition, Quidel will undertake direct commercial responsibility for all BNP sales worldwide.
October 2017—The U.S. Preventive Services Task Force posted on Sept. 12 a draft recommendation statement and draft evidence review on screening for cervical cancer. The task force recommends that primary care clinicians screen for cervical cancer in women who are 21–29 years old every three years with cervical cytology. For women ages 30 to 65, screening is recommended with either cervical cytology alone every three years or with high-risk human papilloma virus (hrHPV) testing alone every five years.
September 2017—Siemens Healthineers showcased its Atellica Solution, flexible, scalable, automation-ready immunoassay and chemistry analyzers for laboratory diagnostics, at the 69th AACC Annual Scientific Meeting and Clinical Lab Expo. The 510(k)-cleared Atellica Solution, for mid- and high-volume labs, comprises sample management and immunoassay and chemistry analyzer components.
September 2017—LGC Maine Standards’ Validate D-Dimer linearity and calibration verification test kit has received FDA 510(k) clearance for use on Siemens Sysmex CS-2500 System analyzers.
September 2017—Ortho Clinical Diagnostics announced a strategic relationship with Brahms GmbH, part of Thermo Fisher Scientific, to develop the Brahms PCT assay for use on Ortho’s Vitros Systems. The Brahms PCT assay is used in conjunction with other laboratory findings and clinical assessment to aid in sepsis management, including early identification of patients at higher risk of progressing to septic shock, identifying when it is safe to discontinue antibiotics, and establishing mortality risk in septic patients.
September 2017—Streck and Inter Medico, a privately owned Canadian distributor of medical diagnostic and research-related products, have signed a distribution agreement for Streck’s cell stabilization and molecular products. Inter Medico will have exclusive distribution rights in Canada to those Streck products.
September 2017—Roche received FDA approval for the Cobas CMV test for use on its Cobas 6800 and Cobas 8800 Systems. The test is standardized to the 1st WHO International Standard for improving harmonization in cytomegalovirus testing results across hospital institutions.
September 2017—Bio-Rad Laboratories has added four analytes to the company’s Liquichek Tumor Marker Control. The updated control received FDA 510(k) clearance and the CE mark and is available for the immunoassay-based tumor marker testing market.
September 2017—Diatron displayed its Aquila three-part differential hematology analyzer at the 69th AACC annual meeting in San Diego. Specifically designed for the decentralized laboratory, this small analyzer has low reagent consumption of less than 12 mL, requires less than 20 µL of whole blood, and has a throughput of up to 60 samples per hour.
September 2017—MedTest’s Pointe Scientific product brand has developed a full line of chemistry reagents that are manufactured and packaged in barcoded reagent containers for use on the BioLis 24i chemistry analyzer, also known as the CLC480 or MGC 240 chemistry analyzer.
